Alzheimer's disease and inflammation: A review of cellular and therapeutic mechanisms

Clinical and Experimental Pharmacology and Physiology

Volumn 27, Issue 1-2, 2000, Pages 1-8

  Halliday, Glenda ^a   Robinson, Stephen R ^c   Shepherd, Claire ^a   Kril, Jillian ^b  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

amyloid; Alzheimer's disease; Anti inflammatory medication; Blood brain barrier; Inflammation; Microglia; Platelets; Senile plaques

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BLOOD BRAIN BARRIER; DRUG MECHANISM; HUMAN; INFLAMMATION; LEPROSY; MEMBRANE PERMEABILITY; MICROGLIA; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SENILE PLAQUE; THROMBOCYTE ACTIVATION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; ENCEPHALITIS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MICROGLIA; NEURONS; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SENILE PLAQUES;

EID: 0033951505     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2000.03200.x     Document Type: Review

References (75)

1. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol. Aging 1997; 18: S1-2.
2. Dickson DW. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 1997; 56: 321-39.
3. Wisniewski T, Ghiso J, Frangione B. Biology of Aβ amyloid in Alzheimer's disease. Neurobiol. Dis. 1997; 4: 313-28.
4. Davies DG, Schmitt FA, Wekstein DR et al. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol 1999; 55: 376-88.
5. Braak H, Braak E. Frequency of stages of Alzeimer-related lesions in different age categories. Neurobiol. Aging 1997; 18: 351-7.
6. Streit WJ, Walter SA, Pennell NA. Reactive microgliosis. Prog. Neurobiol. 1999; 57: 563-81.
7. Neumann H, Wekerle H. Neuronal control of the immune response in the central nervous system: Linking brain immunity to neurodegeneration. J. Neuropathol. Exp. Neurol. 1998; 57: 1-9.
8. Walker DG. Inflammatory markers in chronic neurodegenerative disorders with emphasis on Alzheimer's disease. In: Wood PL (ed.). Neuroinflammation: Mechanisms and Management. Humana Press, Totowa, NJ. 1998; 61-90.
9. Shen Y, Li R, McGeer EG et al. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 1997; 769: 391-5.
10. Eikelenboom P, Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. Aging 1996; 17: 673-80.
11. Goate A, Chartier-Harlin MC, Mullan M et al. Segregation of a missense mutation in the amyloid β protein precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-6.
12. Games D, Adams D, Alessandrini R et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995; 373: 523-7.
13. Donnelly MT, Hawkey CJ. Review article: COX-II inhibitors. A new generation of safer NSAIDs? Ailment. Pharmacol. Ther. 1997; 11: 227-36.
14. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 1998; 38: 97-120.
15. O'Neill GP, Ford-Hutchison AW. Expression of mRNA for cyclooxygenase I and cyclooxygenase II in human tissue. FEBS Lett. 1993; 330: 156-60.
16. Sairanen T, Ristimaki A, Karjalainen-Lindsberg ML et al. Cyclooxygenase-2 is induced globally in infarcted human brain. Ann. Neurol. 1998; 43: 738-47.
17. Kaufmann WE, Worley PF, Pegg J et al. COX-2, a synaptically-induced enzyme, is expressed by excitatory neurons at post-synaptic sites in rat cerebral cortex. Proc. Natl Acad. Sci. USA 1996; 93: 2317-21.
18. Siesjo BK. Free radicals and brain damage. Cerbrovasc. Brain Metab. Rev. 1989; 1: 165-211.
19. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998; 87: 319-24.
20. Nakayama M, Chen J, Lowry T et al. The immediate early gene cyclooxygenase-2 is expressed in CA1 neurons destined for apoptotic death following globalised ischemia. Soc. Neurosci. Abstr. 1995; 21: 1268 (Abstract).
21. Paresce DM, Chung H, Maxfield FR. Slow degradation of aggregates of the Alzheimer's disease amyloid β-protein by microglial cells. J. Biol. Chem. 1997; 272: 29390-7.
22. Giulian D, Haverkamp LJ, Yu JH et al. Specific domains of β-amyloid from Alzheimer plaques elicit neuron killing in human microglia. J. Neurosci. 1996; 16: 6021-37.
23. Button CI, O'Dowd BS, Noone DF et al. Ferritin-rich microglia are concentrated within β-amyloid plaques. Alzheimer Res. 1997; 3: 23-8.
24. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996; 47: 425-32.
25. Jenkinson MI, Bliss MR, Brain AT et al. Rheumatoid arthritis and senile dementia of the Alzheimer type. Br. J. Rheumatol. 1989; 28: 86-7.
26. Blacker D, Wilcox MA, Laird NM et al. α-2 Macroglobulin is genetically associated with Alzheimer's disease. Nature Genet. 1998; 19: 357-60.
27. Papassotiropoulos A, Bagli M, Jessen F et al. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann. Neurol. 1999; 45: 666-8.
28. Curran M, Middleton D, Edwardson J et al. HLA-DR antigens associated with major genetic risk for late-onset Alzheimer's disease. Neuroreport 1997; 8: 1467-9.
29. Pasinetti GL. Cyclooxygenase and inflammation in Alzheimer's disease: Experimental approaches and clinical interventions. J. Neurosci. Res. 1998; 54: 1-6.
30. Roses AD. Apolipoprotein E in neurology. Curr. Opin. Neurol. 1996; 9: 265-70.
31. Richards M, Meade TW, Peart S et al. Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings. J. Neurol. Neurosurg. Psychiatry 1997; 62: 269-72.
32. Rogers J, Kirby LC, Hempleman SR et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-11.
33. Scharf S, Mander A, Ugoni A et al. A double blind placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53: 197.
34. Rich JB, Rasmusson DX, Folstein MF et al. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995; 45: 51-5.
35. McGeer PL, Harada N, Kirura H et al. Prevalence of dementia amongst elderly Japanese with leprosy: Apparent effect of chronic drug therapy. Dementia 1992; 3: 146-9.
36. Namba Y, Kawatsu K, Izumi S et al. Neurofibrillary tangles and senile plaques in the brain of elderly leprosy patients. Lancet 1992; 340: 978.
37. Goto M, Kimura T, Hagio S et al. Neuropathological analysis of dementia in a Japanese leprosarium. Dementia 1995; 6: 157-61.
38. Stewart WF, Kawas C, Corrada M et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48: 626-32.
39. McDowell I, Hill G, Lindsay J et al. The Canadian study of health and aging: Risk factors for Alzheimer's disease in Canada. Neurology 1994; 44: 2073-80.
40. Prince M, Rabe-Hesketh S, Brennan P. Do antiarthritic drugs decrease the risk for cognitive decline? Neurology 1998; 50: 374-9.
41. Henderson AS, Jorm AF, Christensen H et al. Aspirin, anti-inflammatory drugs and risk of dementia. Int. J. Geriatr. Psychiatry 1997; 12: 926-30.
42. -) regulatory pathways. J. Immunol. 1996; 157: 2129-35.
43. Fiebich BL, Lieb K, Hüll M et al. Effects of NSAIDs on IL-1β-induced IL-6 mRNA and protein synthesis in human astrocytoma cells. Neuroreport 1996; 7: 1209-13.
44. Gottschall PE. β-Amyloid induction of gelatinase B secretion in cultured microglia: Inhibition by dexamethasone and indomethacin. Neuroreport 1996; 7: 3077-80.
45. Netland EE, Newtown JL, Majocha RE et al. Indomethacin reverses the microglial response to amyloid β-protein. Neurobiol. Aging 1998; 19: 201-4.
46. Blom MAA, Vantwillert MGH, Devries SC et al. NSAIDs inhibit the IL-β-induced IL-6 release from human post-mortem astrocytes: The involvement of prostaglandin E-2. Brain Res. 1997; 777: 210-18.
47. Landolfi C, Soldo L, Polenzani L et al. Inflammatory molecule release by β-amyloid-treated T98G astrocytoma cells: Role of prostaglandin and modulation by paracetamol. Eur. J. Pharmacol. 1998; 360: 55-64.
48. 2, cyclic AMP and non-steroidal anti-inflammatory drugs. Eur. J. Neurosci. 1997; 9: 934-10.
49. Panegyres PK, Hughes J. The neuroprotective effects of the recombinant interleukin-1 receptor antagonist rhIL-1ra after excitotoxic stimulation with kainic acid and its relationship to the amyloid precursor protein gene. J. Neurol. Sci. 1998; 154: 123-32.
50. 2α on the postsynaptic action of inhibitory and excitatory amino acids in cerebellar Purkinje cell dendrites in vitro. Brain Res. 1985; 330: 235-44.
51. MacKenzie IR, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 1998; 50: 986-90.
52. Selkoe DJ, Podlisny MB, Joachim CL et al. β-Amyloid precursor protein of Alzheimer's disease occurs as 110-135-kilodalton membrane-associated proteins in neural and non-neural tissues. Proc. Natl Acad. Sci. USA 1988; 85: 7341-5.
53. Bush AI, Martins RN, Rumble B et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J. Biol. Chem. 1990; 265: 15 977-83.
54. Li OX, Whyte S, Tanner JE et al. Secretion of Alzheimer's disease Aβ amyloid peptide by activated human platelets. Lab. Invest. 1998; 78: 461-9.
55. Smith CCT. Stimulated release of the β-amyloid protein of Alzheimer's disease by normal human platelets. Neurosci. Lett. 1997; 235: 157-9.
56. Scheuner D, Eckman C, Jensen M et al. Secreted amyloid β protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 1996; 2: 864-70.
57. Hershkowitz M, Adunsky A. Binding of platelet-activating factor to platelets of Alzheimer's disease and multi-infarct dementia patients. Neurobiol. Aging 1996; 17: 865-8.
58. Wolozin B, Maheshwari S, Jones C et al. β-Amyloid augments platelet aggregation: Reduced activity of familial angiopathy-associated mutants. Mol. Psychiatry 1998; 3: 500-7.
59. Sevush S, Jy W, Horstman LL et al. Platelet activation in Alzheimer's disease. Arch. Neurol. 1998; 55: 530-6.
60. Pennisi E. Building a better aspirin. Science 1998; 280: 1191-2.
61. Zlokovic B. Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer disease pathology? Neurobiol. Dis. 1997; 4: 23-6.
62. Mackic JB, Weiss MH, Mhao W et al. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid β peptide in aged squirrel monkey with cerebral amyloid angiopathy. J. Neurochem. 1998; 70: 210-15.
63. Jansco G, Domoki F, Santha P et al. β-Amyloid (1-42) peptide impairs blood-brain barrier function after intracarotid infusion in rats. Neurosci. Lett. 1998; 253: 139-41.
64. Su GC, Arendash GW, Kalaria RN et al. Intravascular infusions of soluble β-amyloid compromise blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res. 1999; 818: 105-17.
65. Crawford F, Suo Z, Fang C et al. Characteristics of the in vitro vaso-activity of β-amyloid peptides. Exp. Neurol. 1998; 150: 159-68.
66. Paris D, Town T, Parker TA et al. Isoform specific vasoconstriction induced by apolipoprotein E and modulation of this effect by Alzheimer's β-amyloid peptide. Neurosci. Lett. 1998; 256: 73-6.
67. Suo Z, Humphrey J, Kundtz A et al. Soluble Alzheimers B-amyloid constricts the cerebral vasculature in vivo. Neurosci. Lett. 1998; 257: 77-80.
68. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: Does acute endothelial dysfunction provide a link? Lancet 1997; 349: 1391-2.
69. Caserta MT, Caccioppo D, Lapin GD et al. Blood-brain barrier integrity in Alzheimer's disease patients and elderly control subjects. J. Neuropsych. Clin. Neurosci. 1998: 10: 78-84.
70. Skoog I, Wallin A, Fredman P et al. A population study on blood brain barrier function in 85-year-olds: Relation to Alzheimer's disease and vascular dementia. Neurology 1998; 50: 966-71.
71. Snowdon DA, Griener LH, Mortimer JA et al. Brain infarction and the clinical expression of Alzheimer disease. JAMA 1997; 277: 813-17.
72. Olichney JM, Sabbagh MN, Hofstetter CR et al. The impact of apolipoprotein E4 on cause of death in Alzheimer's disease. Neurology 1997; 49: 76-81.
73. Zhang Z, Chopp M, Powers C. Temporal profile of microglial response following transient (2 h) middle cerebral artery occlusion. Brain Res. 1997; 744: 189-98.
74. Zhang F, Eckman S, Hsiao KK et al. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J. Neurosci. 1997; 17: 7655-61.
75. Algra A, van Gijn J, Koudstaal PJ. Secondary prevention after cerebral ischemia of presumed arterial origin: Is aspirin still the touchstone? J. Neurol. Neurosurg. Psychiatry 1999; 66: 557-9.